{"ticker": {"uuid": "67d00e45-75b2-4ca0-8350-44ee3d6fc7d0", "symbol": "DNLI", "name": "Denali Therapeutics Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Denali Therapeutics Price Target Announced at $29.00/Share by JP Morgan", "summary": "JP Morgan has set a price target of $29.00 per share for Denali Therapeutics, indicating their valuation of the company's stock. This announcement provides investors with an analyst's perspective on the potential future trading price of Denali Therapeutics.", "url": "https://www.moomoo.com/news/post/72857166/denali-therapeutics-price-target-announced-at-29-00-share-by?futusource=news_newspage_recommend", "source_name": "Moomoo", "published_at": "2026-07-14T02:13:09", "published_display": "14 Jul 2026 02:13", "sentiment": "positive", "sentiment_pct": 65, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Wedbush Raises Price Target on Denali Therapeutics to $26 From $20, Keeps Outperform Rating", "summary": "Wedbush has increased its price target for Denali Therapeutics (NASDAQ: DNLI) from $20 to $26, while maintaining an Outperform rating on the stock. This adjustment reflects Wedbush's continued positive outlook on the company's prospects.", "url": "https://www.moomoo.com/news/post/72858399/wedbush-raises-price-target-on-denali-therapeutics-to-26-from?futusource=news_newspage_recommend", "source_name": "Moomoo", "published_at": "2026-07-13T14:10:47", "published_display": "13 Jul 2026 14:10", "sentiment": "positive", "sentiment_pct": 70, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Denali Therapeutics (DNLI) Secures Overweight Rating from JPMorg", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxQYVdqbWlGbDh5TTVlSGtKb1pFN21OUmc4SmRpNVJyWnZqT2lXaHMyaFFDa0NNUnJJSmxLX3BWZ2phNVVQMEkwY0NaTy1tNkJVZjlMaVJVMnFqSm1idDMyVi1laVdCU2xranRORDllYmJIcXVKVW52Y0tpb2Zzc1VQOG5sR0hGVDNQUHR0VTg4WDlCaGxBWTFVckViWUlqMm5rS1NYRHhlQUo0U3ZRNVowYzFLWWtyeU1XM0E?oc=5", "source_name": "GuruFocus", "published_at": "2026-07-13T10:50:16+00:00", "published_display": "13 Jul 2026 10:50", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "JPMorgan resumes Denali Therapeutics stock coverage with Overweight rating", "summary": "JPMorgan has resumed coverage of Denali Therapeutics (NASDAQ:DNLI) with an Overweight rating and a $29 price target, citing its transition to a commercial biotech following the approval of Avlayah. The firm anticipates accelerated approval for DNL126 by late 2027 and highlights a", "url": "https://www.investing.com/news/analyst-ratings/jpmorgan-resumes-denali-therapeutics-stock-coverage-with-overweight-rating-93CH-4787580", "source_name": "Investing.com", "published_at": "2026-07-13T08:09:46", "published_display": "13 Jul 2026 08:09", "sentiment": "positive", "sentiment_pct": 81, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Denali Therapeutics (DNLI) Investor Day 2025 Summary", "summary": "Denali Therapeutics (DNLI) held its 2025 Investor Day, highlighting an expanded strategic focus beyond neurodegeneration to whole-body biotherapeutics using its Transferrin Receptor-enabled TransportVehicle (TV/Tivi) platform. The company aims for two near-term launches, tivideno", "url": "https://quartr.com/events/denali-therapeutics-inc-dnli-investor-day-2025_ojsNzDdr", "source_name": "Quartr", "published_at": "2026-07-10T17:09:55", "published_display": "10 Jul 2026 17:09", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "T. Rowe Price\u2019s 10% Stake and Avlayah Approval Could Be A Game Changer For Denali Therapeutics (DNLI)", "summary": "T. Rowe Price Investment Management has disclosed a 10.2% stake in Denali Therapeutics, shortly after the company secured FDA approval for its Hunter syndrome therapy, Avlayah, and sold a Rare Pediatric Disease Priority Review Voucher for $195 million. This institutional interest", "url": "https://www.sahmcapital.com/news/content/t-rowe-prices-10-stake-and-avlayah-approval-could-be-a-game-changer-for-denali-therapeutics-dnli-2026-07-09", "source_name": "Sahm", "published_at": "2026-07-10T15:09:55", "published_display": "10 Jul 2026 15:09", "sentiment": "positive", "sentiment_pct": 65, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Denali Therapeutics to Give Opening Plenary Address at Alzheimer\u2019s Association International Conference (AAIC) 2026 and Highlight Breakthroughs in Delivering Biologic Therapies Across Blood-Brain Barrier", "summary": "Denali Therapeutics will deliver the opening plenary address at the Alzheimer\u2019s Association International Conference (AAIC) 2026, with CEO Ryan Watts discussing advancements in treating neurodegenerative diseases, particularly Alzheimer's. The company will highlight its proprieta", "url": "https://www.manilatimes.net/2026/07/10/tmt-newswire/globenewswire/denali-therapeutics-to-give-opening-plenary-address-at-alzheimers-association-international-conference-aaic-2026-and-highlight-breakthroughs-in-delivering-biologic-therapies-across-blood-brain-barrier/2381996", "source_name": "The Manila Times", "published_at": "2026-07-10T02:40:30", "published_display": "10 Jul 2026 02:40", "sentiment": "positive", "sentiment_pct": 93, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Denali CEO to open AAIC 2026 with brain-delivery plan for Alzheimer\u2019s", "summary": "Denali Therapeutics (Nasdaq: DNLI) announced that co-founder and CEO Ryan Watts, Ph.D., will deliver the opening plenary address at the Alzheimer\u2019s Association International Conference (AAIC) 2026 in London. He will discuss advancements in neurodegeneration biology, biomarkers, a", "url": "https://www.stocktitan.net/news/DNLI/denali-therapeutics-to-give-opening-plenary-address-at-alzheimer-s-4ujviltygake.html", "source_name": "Stock Titan", "published_at": "2026-07-09T19:40:32", "published_display": "09 Jul 2026 19:40", "sentiment": "positive", "sentiment_pct": 76, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Denali Therapeutics stock hits 52-week high at $26.95", "summary": "Denali Therapeutics Inc. (DNLI) stock recently hit a 52-week high of $26.95, reflecting a 73.88% increase over the past year. The company's market cap is $4.24 billion, but InvestingPro suggests it might be overvalued. Recent positive news includes the sale of a Rare Pediatric Di", "url": "https://www.investing.com/news/company-news/denali-therapeutics-stock-hits-52week-high-at-2695-93CH-4784278", "source_name": "Investing.com", "published_at": "2026-07-09T14:40:32", "published_display": "09 Jul 2026 14:40", "sentiment": "positive", "sentiment_pct": 75, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Denali Therapeutics stock hits 52-week high at $26.95 By Investing.com", "summary": "Denali Therapeutics Inc. (DNLI) stock has reached a new 52-week high of $26.95, reflecting a 73.88% increase over the past year. The company's market cap is $4.24 billion, with InvestingPro suggesting potential overvaluation. Recent developments include selling a Rare Pediatric D", "url": "https://ca.investing.com/news/stock-market-news/denali-therapeutics-stock-hits-52week-high-at-2695-93CH-4727589", "source_name": "Investing.com Canada", "published_at": "2026-07-09T13:42:29", "published_display": "09 Jul 2026 13:42", "sentiment": "positive", "sentiment_pct": 94, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "DNLI Stock Surges 59.4% Year to Date: Is There More Room for Growth?", "summary": "Denali Therapeutics (DNLI) has seen its stock surge 59.4% year-to-date, driven by the FDA approval of Avlayah for Hunter syndrome and investor optimism. The approval establishes Denali as a commercial-stage company and validates its TransportVehicle platform, positioning it for l", "url": "https://www.tradingview.com/news/zacks:71454ca0c094b:0-dnli-stock-surges-59-4-year-to-date-is-there-more-room-for-growth/", "source_name": "TradingView", "published_at": "2026-07-08T17:41:29", "published_display": "08 Jul 2026 17:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "T. Rowe Price holds 10.2% of Denali Therapeutics (DNLI) in 13G/A", "summary": "T. Rowe Price Investment Management, Inc. has disclosed a 10.2% stake in Denali Therapeutics (DNLI) through a Schedule 13G/A filing. The filing indicates beneficial ownership of 16,178,963 shares, with T. Rowe Price holding sole voting power for 15,639,355 shares and sole disposi", "url": "https://www.stocktitan.net/sec-filings/DNLI/schedule-13g-a-denali-therapeutics-inc-amended-passive-investment-dis-df6d72096984.html", "source_name": "Stock Titan", "published_at": "2026-07-08T15:41:29", "published_display": "08 Jul 2026 15:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "DNLI - Denali Therapeutics Inc Volatility & Greeks", "summary": "This article provides a detailed financial overview of Denali Therapeutics Inc. (DNLI), including its latest stock performance, key financial ratios, volatility metrics, and insider/institutional ownership data. It covers various performance indicators like EPS, sales growth, and", "url": "https://finviz.com/stock?t=DNLI&p=m&ty=ocv&ov=chain_strike&s=40", "source_name": "Finviz", "published_at": "2026-07-06T18:13:45", "published_display": "06 Jul 2026 18:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Denali Therapeutics (DNLI) Looks Fully Valued Following Its 32% 30 Day Rally", "summary": "Denali Therapeutics (DNLI) has seen a significant rally, with a 30-day return of 32.33% and a one-year return of 75.83%. Despite trading at a discount to the average analyst price target, the company's Price-to-Book ratio of 4.4x (compared to the industry average of 2.8x) suggest", "url": "https://www.sahmcapital.com/news/content/denali-therapeutics-dnli-looks-fully-valued-following-its-32-30-day-rally-2026-07-05", "source_name": "Sahm", "published_at": "2026-07-06T01:13:46", "published_display": "06 Jul 2026 01:13", "sentiment": "negative", "sentiment_pct": 38, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "DNLI - Denali Therapeutics Inc Latest SEC Filings", "summary": "This page provides a detailed financial overview and snapshot of Denali Therapeutics Inc. (DNLI), including its latest stock performance, key financial metrics, insider and institutional ownership, and analyst recommendations. It also lists the company's SEC filings and provides ", "url": "https://finviz.com/stock?t=DNLI&p=w&r=y2&ty=lf&page=17", "source_name": "Finviz", "published_at": "2026-07-05T12:42:56", "published_display": "05 Jul 2026 12:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Denali Therapeutics stock stays focused on pipeline progress.", "summary": "Denali Therapeutics' stock performance is closely tied to the progress of its neuroscience and lysosomal disease pipeline, with investors monitoring development milestones. The company's focus on transport vehicle technology to cross the blood-brain barrier is central to its drug", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/denali-therapeutics-stock-stays-focused-on-pipeline-progress/69682194", "source_name": "Ad-hoc-news.de", "published_at": "2026-07-03T17:41:09", "published_display": "03 Jul 2026 17:41", "sentiment": "positive", "sentiment_pct": 65, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Amyotrophic Lateral Sclerosis Market Gains Momentum with Expanding Pipeline and Investment Potential by 2034 \u2013 DelveInsight | Helixmith, Sanofi, Denali Therapeutics, Transposon Therapeutics, GSK", "summary": "The Amyotrophic Lateral Sclerosis (ALS) market is projected to expand significantly by 2034, driven by an increasing disease prevalence, advancements in drug development, and growing regulatory support. The market experienced an estimated size of USD 850 million in the United Sta", "url": "https://www.barchart.com/story/news/3078022/amyotrophic-lateral-sclerosis-market-gains-momentum-with-expanding-pipeline-and-investment-potential-by-2034-delveinsight-helixmith-sanofi-denali-therapeutics-transposon-therapeutics-gsk", "source_name": "Barchart.com", "published_at": "2026-07-01T23:10:47", "published_display": "01 Jul 2026 23:10", "sentiment": "positive", "sentiment_pct": 71, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Denali Therapeutics Inc. \u2013 NASDAQ:DNLI", "summary": "This article focuses on the enterprise value to EBIT forward metric for Denali Therapeutics Inc. (NASDAQ: DNLI). It presents financial data related to this specific valuation ratio for the biotechnology company. The content appears to be a stub or a section from a financial data ", "url": "https://www.tradingview.com/symbols/NASDAQ-DNLI/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T23:11:29", "published_display": "27 Jun 2026 23:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Denali Therapeutics Inc. \u2013 NASDAQ:DNLI", "summary": "This article provides a financial statistic for Denali Therapeutics Inc. (NASDAQ: DNLI). Specifically, it presents the \"Price to sales forward\" metric for the company. The content appears to be a snapshot from a financial data platform, likely TradingView, showing overview inform", "url": "https://www.tradingview.com/symbols/NASDAQ-DNLI/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T08:10:48", "published_display": "27 Jun 2026 08:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Denali Therapeutics Inc Shs Unsponsored Brazilian Depositary Receipt Repr 0.2 Sh", "summary": "This page displays financial information for Denali Therapeutics Inc Shs Unsponsored Brazilian Depositary Receipt Repr 0.2 Sh (BMFBOVESPA:D2NL34), specifically its price-to-sales forward ratio. The content appears to be a financial data presentation page from TradingView, offerin", "url": "https://www.tradingview.com/symbols/BMFBOVESPA-D2NL34/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T01:40:02", "published_display": "27 Jun 2026 01:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Denali Therapeutics Inc. \u2013 NASDAQ:DNLI", "summary": "This page provides financial data, specifically the \"Price to earnings forward\" for Denali Therapeutics Inc. (NASDAQ: DNLI). It indicates that the company's stock is listed on the Nasdaq Stock Market and that the market was closed at the time of the data query, with no trades hav", "url": "https://www.tradingview.com/symbols/NASDAQ-DNLI/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T00:40:01", "published_display": "27 Jun 2026 00:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Denali Therapeutics Inc. Actuals & Estimates (DUS:4DN)", "summary": "This article provides an overview of Denali Therapeutics Inc. (DUS:4DN) financials, analyst estimates, and historical stock performance. It includes details on revenue, earnings per share, net income, key dates like the next earnings report on July 30, 2026, and a stock forecast ", "url": "https://www.tradingview.com/symbols/DUS-4DN/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T21:39:56", "published_display": "26 Jun 2026 21:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Denali Therapeutics Inc. \u2013 NASDAQ:DNLI", "summary": "This article provides the enterprise value to EBITDA forward for Denali Therapeutics Inc. (NASDAQ: DNLI). It appears to be a financial data snippet from TradingView, concentrating solely on this specific financial metric for the biotechnology company. The content confirms that no", "url": "https://www.tradingview.com/symbols/NASDAQ-DNLI/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T21:10:49", "published_display": "26 Jun 2026 21:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Denali Therapeutics Inc. Actuals & Estimates (NASDAQ:DNLI)", "summary": "This article provides an overview of Denali Therapeutics Inc. (NASDAQ: DNLI) stock, including current prices, historical performance, analyst forecasts, and financial data. It highlights the company's recent stock growth, market capitalization, and upcoming earnings report date, ", "url": "https://www.tradingview.com/symbols/NASDAQ-DNLI/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T20:40:02", "published_display": "26 Jun 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How Denali Therapeutics Inc. (DNLI) Affects Rotational Strategy Timing", "summary": "This article analyzes Denali Therapeutics Inc. (DNLI) using AI models to determine its impact on rotational strategy timing. It highlights strong sentiment across all horizons supporting an overweight bias and identifies no resistance levels above the current price, suggesting si", "url": "https://news.stocktradersdaily.com/news_release/150/How_Denali_Therapeutics_Inc._DNLI_Affects_Rotational_Strategy_Timing_062526083001_1782433801.html", "source_name": "Stock Traders Daily", "published_at": "2026-06-25T20:30:00", "published_display": "25 Jun 2026 20:30", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Denali Therapeutics options trading jumps to 2,291 contracts", "summary": "Denali Therapeutics Inc. saw a significant increase in options trading, with 2,291 contracts traded by Thursday afternoon. Call volume heavily outweighed put volume, and the July 17, 2026 $30 call option was particularly active. Coinciding with this, Denali Therapeutics shares ex", "url": "https://www.investing.com/news/stock-market-news/denali-therapeutics-options-trading-jumps-to-2291-contracts-93CH-4761252", "source_name": "Investing.com", "published_at": "2026-06-25T18:09:57", "published_display": "25 Jun 2026 18:09", "sentiment": "positive", "sentiment_pct": 61, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Denali to Sell Priority Review Voucher for $195M Cash Boost", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/denali-sell-priority-review-voucher-124000184.html", "source_name": "Zacks", "published_at": "2026-06-19T12:40:00+00:00", "published_display": "19 Jun 2026 12:40", "sentiment": "negative", "sentiment_pct": 42, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Denali Therapeutics to Sell its Rare Pediatric Disease Priority Review Voucher for $195 Million", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/denali-therapeutics-sell-rare-pediatric-122056186.html", "source_name": "MT Newswires", "published_at": "2026-06-18T12:20:56+00:00", "published_display": "18 Jun 2026 12:20", "sentiment": "negative", "sentiment_pct": 42, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Denali\u2019s rare disease voucher sale brings in $195 million", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxPb3BObzBPQzNOVUg3OU9xNGtkVG44Y0FyZUFVX0xHbmM3UXdzX3lHVHJ0bDNGdks1QVpmNDAtaGpJbk5mZDBLcVZUSk5rY2kxT0RHZ0NDRVlTTjBjOTVZSmNMZWNucEwwcTZiVW02d3VNaDV3REs5NFV2OUE2V0wzWkItRUJlaF91dmN1c2hKYk05VDJKaFhGNDZEVW5UQks4cXdwZEM4U25LQk0xV1NUVVFtVV81WFJMMlBZdkNPYw?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-18T07:00:00+00:00", "published_display": "18 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Denali Therapeutics (Nasdaq: DNLI) to sell pediatric priority review voucher for $195M", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxPNWY1aFJ1ZTkwR0dLQmtLRDItSmhtTHRqODVnNzlkbHZCeGNCQ3pjdGJqYnNmQmljbDk2aGRQVGI4UEc4Q21hMG5wS05SY0cxSDZIR3V6TGE4eXkwWldMUWVBX09zbWZESV9pa3RZSlNsdURPc25ENU5QTDVvdmZoWk1QdkRqSjk4eU1BalNIVWxpWDhfTzdwamNGa0Z4b2dDS0h5V3VEWjh2bzREMzdyNWZ3?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-18T07:00:00+00:00", "published_display": "18 Jun 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "UBS reiterates Denali Therapeutics stock rating citing Avlayah launch", "summary": "", "url": "https://news.google.com/rss/articles/CBMiyAFBVV95cUxOdzlmQTlNY2FCVzJLTW82RTl2cXRSc0F5cDB4NnB5YjNWRUV6a2ZHTURIRjR1S0FqQUNmLVRKeGxpeHJlekZmcVIyTlpmaFBhcHVDa0lzQ3dEdXNaYVVRVlBPb29haG9fdjI2b2N6ODlDanA5UDlNbFdhMTRjeW5hM0hPaXQyNUZicUVoWXJQTUxNS29rLXF5ZFQ1UkpqZnZFMlVaaWtSRWR5akIzSXJGdmdxOE9ScTJlLTZNbl9jTG41STRoVU1tVw?oc=5", "source_name": "Investing.com", "published_at": "2026-06-16T07:00:00+00:00", "published_display": "16 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What Makes Denali Therapeutics (DNLI) One of the Best AI Driven Biotech Names", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxPSWRBT3RMdVo2Tm1LYkVNRlRlTmhUclYwZkhfWlhncE1hdk9HdkY5ZFQyQ1lDU2J0YkZGYWVBQ2dvdGFEamQ3Nk90ajAwUmdMM1FybVdyNDJMbWhBVU91SWp2TlJrYXhLdm8yeVFCc25sRTJGV0hKU0FNYWFXRV90Nklka0NsMHNwR0dxdWt4d3Zic0xTOFBzamItWmVtQ3FGb0czOVNR?oc=5", "source_name": "Market source", "published_at": "2026-06-11T07:00:00+00:00", "published_display": "11 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Denali Therapeutics (DNLI) grants RSUs and stock options to director", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxNekNnanJHXzFXN3c0a0FEVHcwWG5CUTBaMGNDWUdhbDdOV0s0cW1NaVo5R0tQSlJfTkx5eGMwUDFlcENJcTJfWFBNaGNLN3J2d2FydzhtbW1yUHlIcjREQzgxenBGdVlTSDVqT2twTVgtRm5nYzhNR29xTDRyVmhJWnNYUTJjazRVR1V3ZUdlOWRyMEtndHVnQ21zNUhoblVFUE80anJzTFlHNFZEd3g1UzVSS0V2TW13?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-05T07:00:00+00:00", "published_display": "05 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Denali Therapeutics (DNLI) 2026 meeting backs board slate, auditor and executive pay", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxNazYzSTZIcmstZlpDTmJ5TVBGb09EcFowYnNvcWJwUE0zS3BHTGhXWUZUSUR5TlVBcWlMNnRuU2ZTZEE0SkMydXBDY05OWlo4TjZzZFVpcGRUellmQVZtdGx3aGNKX2x5dzRQbzJOSE9JOFkyTWktZHdCbVRUZUlFYUlxcE9HYXY5Y3dTYVVBT2lndzZwVDkyaGhEWWY2bjhURkRadF9tYVc1OWI1czRfS1FR?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-04T07:00:00+00:00", "published_display": "04 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Denali Therapeutics Inc. (DNLI): One of the Top Stock Picks of Jeff Bezos", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxNM2JzbzhYejFkcWFDYUhNNGZQX3BNcFJFUFVVQ0Y5T21iSDY4X3RLblROT0Z4QnpEZ2VDSHNQYnZ4RmwtRmdUSzIyV1RvbjNnWmVxeVg5UTN4dE9EaENRRGNXUTJzcFZDcmd2LXhwdFM4RUltNWNhSldRMDZ0bEpmcERtbHVxdGgwU0s4bGdNcVpQSjRlYWpMSVhHY2lVQQ?oc=5", "source_name": "Market source", "published_at": "2026-06-01T07:00:00+00:00", "published_display": "01 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Denali Stock Dips as Biogen-Partnered Parkinson's Disease Study Fails", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxPNzJEZFk3a2MxcHU0QjdKMEZpWDhmaXlMVUNGSnM1NERseVJ1YXlONlY4NzRoYmVQU3cyaXhsVFE0SEZYcTZkcHNvcjhxRFBZQW5TY0dKekI5ZmZQM3VNZUFxSlN4ZW9jSi1RaWtPdk9QVDY3RFRpdnRjWmhtdmdYV29GeTRRZFhSX28tNHczeGp5N2RxYmFCSHdMSGlxSFlTWDd2TnhB?oc=5", "source_name": "Market source", "published_at": "2026-05-22T07:00:00+00:00", "published_display": "22 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Denali\u2019s AVLAYAH Approval Shifts Focus To Valuation And Pipeline Potential", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-19T07:00:00+00:00", "published_display": "19 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Hedge Fund Wagers $36 Million on Biotech Denali After First FDA Approval", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwgFBVV95cUxOcGoyV29uOWdIZHVWZHFZYVYwUnlGcHNlNmNPNGsyUHlGN21qclN2RlBSMmNhUW1va3U3YjJ6N3k4UHFUQkQ1dUxNWHBCaGNOSEt5c0ozV1drcno5Y1BqOXFnVnd1Rl9QN0RKVUlKcFRrZWllQVJCVlhtTWM3MUcxWlRSaXhJNFFYRVBNanBSblZuNlFUdlJzQ3hhTXZ3US1OZVFad19PUnUxa0tlREtCZDB5aHN3QzhIQ2xQYWFjandSQQ?oc=5", "source_name": "The Motley Fool", "published_at": "2026-05-18T07:00:00+00:00", "published_display": "18 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "FMR LLC increases visibility on Denali (DNLI): 6.67M shares disclosed", "summary": "", "url": "https://news.google.com/rss/articles/CBMiywFBVV95cUxNbkF0cFNZZmVjS1dNd0F2ZF90NTE1bUZsR3NvWlQwOUREOW52NkFoRXEwUjJVRjBTS0g4VkFheDNNZ1pxVm5pekJyclIyNHlxRTRFWVFFVWppSzNTTmEwcF9hNTB2Nm5MWGNoTFRjMG1aYXppNEVRc0ZlLTJ4Mi1nNWlJMkJEcE1Jcm1nUjNSbm1IRHloNjNTOWhSZWZJUW1QZmZRMG5LX2ZXQW5IMjZQbV9yLW13UGJibGwzVXNJa091MmdndTNwWjYxTQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Denali Therapeutics (DNLI) Is Down 8.2% After Takeda Exits DNL593 Collaboration And Returns Rights", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxPVy03b1FLTDBYZHRnQTVadzJ0ZlRPdjhFaTh2QXZDcUN4TkVDUVVKcXhBNWotMmRxaHJ5dWdkRDNpeWdLUHhNQWEySjUwNTJiaF9GMFA2YWNiX1VaRFZoYzBDTmJxbkluNktXTDg3aUo0YVd2OWI0eUhEbm1oOW1uUVg1dl8taERKTUpRaUg5eWFfR2FiRkhlSExPeWV6VndHR3R4Tw?oc=5", "source_name": "Market source", "published_at": "2026-05-04T07:00:00+00:00", "published_display": "04 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What Makes Denali Therapeutics (DNLI) One of the Best Biotech Stocks to Invest in", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxPZGU1Z0ZrTnFtWlBBZERaTUVTbXN0Wk02YzdScVc3U21VM2JSS25HcGItUllzbElxdWE4emo4MEd1aWZKSmpuVlBsSkZhMmVSY0xRSTdtdk1JZmhid2Y5SmZRRzNGeVdyNHBleV9IS0FWR1VJTXFhS21IMUF4U3ZhUERPNVJyMkRuLXZxQmFYRDFOelJtWTN1aHpESTY1ZFJ1dFlZczV3?oc=5", "source_name": "Market source", "published_at": "2026-04-29T07:00:00+00:00", "published_display": "29 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Denali Stock Falls as Partner Takeda Ends Collaboration Deal", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxQMTBvOVdzbWI3aG9iamN6RE9aUG1pdGxxZkk4TUZDaHg4aHJPLUpwWlRLOVNrblY3VGlIbnlFV2tYZEs3MVhrVm5Ka1h3ZFdQSGt4WjVrQndyUW1XQ3ZDaHFRZTluTmltNUJKdDh4UjNCWE1MajVkX1lLVi01Vk8wc2c5enVJZEVQbWc2YmJJcnFabTFOYzJVQk9hNWZQX2ZPVG1HTg?oc=5", "source_name": "Market source", "published_at": "2026-04-07T07:00:00+00:00", "published_display": "07 Apr 2026 07:00", "sentiment": "negative", "sentiment_pct": 22, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Takeda exits dementia drug pact, Denali targets trial data by 2026 end", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxNVURNZVUzSE85NGRuLXNPN3k4ejNfampqM0F1V01qWEh2RjBBM2RsdFZlckhkVnJWX3B2a2JYOERUQ0JqaVJ1UjdycVh3OHV4X3BGTXoxN2gyOVphNk5MUVZvVzJ0Y2FOSDNIVkhMVHFvUU5FaENxQ1Qxb2JzYjBKdHRrUEdtb28xX2tQdnVJNk9LakYteVY5SzNkVmNaVVhfcWlaamdJSElzdjQ0clMtNFdXSUxBR1NpRzR3VXhn?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-03T07:00:00+00:00", "published_display": "03 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is It Time To Revisit Denali Therapeutics (DNLI) After Recent Share Price Pullback", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-04-02T07:00:00+00:00", "published_display": "02 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Denali Wins FDA Nod for Hunter Syndrome Drug, Stock Up", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxQUGpMaFlnTzA2eUliR3A1RkJwWDFOMlF6b1RQZzVYbmZkYWdfWURGanQ1SDM0Vk96bUtwTnp4d2ZNNHp6UXNaN0E5enNOREw4LWxNWG9JWjNUWFJwZmlSLXVQLVY4Nmg1dE8xTy04YnhyQjQwRWdUVVFIR0F6Q0RPX2JMbUpld0wtc2kxLU5VSzB6VmhKSUNzVDJ2SQ?oc=5", "source_name": "Market source", "published_at": "2026-03-26T07:00:00+00:00", "published_display": "26 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Goldman Sachs raises Denali Therapeutics stock price target on FDA approval", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0AFBVV95cUxPU0hZYmtHbzZQclRJWDhzV1hfaVMtRGhoaDVxc0JNWVRkM2pXYjJPaTJKWHlqV3ZJTTl4UTdFV1hpYWZOalhMOXhXNjUyZ3R1LXFPRFhXNXhCZ1ZIbExCeDhqSmUxX3pNUk01eERaQi16d0xHWFphX2lGRl9XNGhVQ2lWaV9LLW96Q3RxVGE2dl9kT3A1OTRxdzZWVnZhaEYxNHlSMmlhMUZvQ2FXT1YwbXVxd0pGaDZ6M3JfSUVldWlJcnI3ZE1HV3VXLVl1WmVQ?oc=5", "source_name": "Investing.com", "published_at": "2026-03-25T07:00:00+00:00", "published_display": "25 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Early FDA wins: Corcept\u2019s Lifyorli, Denali\u2019s Avlayah", "summary": "", "url": "https://news.google.com/rss/articles/CBMikwFBVV95cUxQUzRWTzBFbklkUmVGcWl6OFMtdm5lN0FCcWlQWTA3S28yMHVfb1JRbXpSN1BMZjNVUWFIMEEtalRYMFBQbDk1SjNmVVFwMjJlQ0QwRm15UUNQRzRndHpOWXFxRUVuLXlTdWFPclpxdkI1VmdPd0lrWDZOMVhENlViYXhTVXNwWDlaWk15WnVSajF5SkU?oc=5", "source_name": "BioWorld News", "published_at": "2026-03-25T07:00:00+00:00", "published_display": "25 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Denali Gains 11.8% in a Month: Buy, Sell or Hold the Stock?", "summary": "", "url": "https://news.google.com/rss/articles/CBMieEFVX3lxTFBGUFhxSHNJUk9mWEc2SkxZamlPUjRGQy1KZGhlc1pFS3hLUDRfWTMwcXpDbzJYRHRjbzA4U0ZLdlE3T2FOWmdGdFFIck9TbnZQb2Rxb2F0NGtzQjdaUlNGNUNWRndrZzkxNVhlOHFFMkVCUjN3ZFlpUQ?oc=5", "source_name": "Market source", "published_at": "2026-03-11T07:00:00+00:00", "published_display": "11 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Denali Therapeutics Inc (DNLI) Stock Price Today & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiV0FVX3lxTE1qbklvMzFzWU9UR0MydVVSSDNvd0RMdFhtZi1GOUJiS0JneXpFUEg1NkljdWE1bXBTVG1vRHlubzl3V1pxN3UtV3ZuQ2VfRE83WUx2dDhaYw?oc=5", "source_name": "Gotrade", "published_at": "2026-01-25T15:56:45+00:00", "published_display": "25 Jan 2026 15:56", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Have Denali Therapeutics Insiders Been Selling Stock?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-01-11T08:00:00+00:00", "published_display": "11 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Denali Therapeutics (DNLI) the Most Promising Mid-Cap Healthcare Stock Under $50?", "summary": "", "url": "https://news.google.com/rss/articles/CBMijgFBVV95cUxNSWdDZVVSaGNvSWRRUWZ5UWhUWFl2c2w3TXJqQmtOcjlxTU1ZY0t2aHozdnJGMUxCNDRuMDFpMHZiRGUzSzhIWWp6SnRwSE5kX3QzVGV0UmlHZmZweVZXWnRKM1owODZlUlA4VjY5SVVsNnVmanIza0thODd4MTRzTHgzbng4b2FTYkMtTTZ3?oc=5", "source_name": "Market source", "published_at": "2025-12-22T08:00:00+00:00", "published_display": "22 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Denali Therapeutics Price Target Announced at $29.00/Share by JP Morgan", "summary": "JP Morgan has set a price target of $29.00 per share for Denali Therapeutics, indicating their valuation of the company's stock. This announcement provides investors with an analyst's perspective on the potential future trading price of Denali Therapeutics.", "url": "https://www.moomoo.com/news/post/72857166/denali-therapeutics-price-target-announced-at-29-00-share-by?futusource=news_newspage_recommend", "source_name": "Moomoo", "published_at": "2026-07-14T02:13:09", "published_display": "14 Jul 2026 02:13", "sentiment": "positive", "sentiment_pct": 65, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Wedbush Raises Price Target on Denali Therapeutics to $26 From $20, Keeps Outperform Rating", "summary": "Wedbush has increased its price target for Denali Therapeutics (NASDAQ: DNLI) from $20 to $26, while maintaining an Outperform rating on the stock. This adjustment reflects Wedbush's continued positive outlook on the company's prospects.", "url": "https://www.moomoo.com/news/post/72858399/wedbush-raises-price-target-on-denali-therapeutics-to-26-from?futusource=news_newspage_recommend", "source_name": "Moomoo", "published_at": "2026-07-13T14:10:47", "published_display": "13 Jul 2026 14:10", "sentiment": "positive", "sentiment_pct": 70, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Denali Therapeutics (DNLI) Secures Overweight Rating from JPMorg", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxQYVdqbWlGbDh5TTVlSGtKb1pFN21OUmc4SmRpNVJyWnZqT2lXaHMyaFFDa0NNUnJJSmxLX3BWZ2phNVVQMEkwY0NaTy1tNkJVZjlMaVJVMnFqSm1idDMyVi1laVdCU2xranRORDllYmJIcXVKVW52Y0tpb2Zzc1VQOG5sR0hGVDNQUHR0VTg4WDlCaGxBWTFVckViWUlqMm5rS1NYRHhlQUo0U3ZRNVowYzFLWWtyeU1XM0E?oc=5", "source_name": "GuruFocus", "published_at": "2026-07-13T10:50:16+00:00", "published_display": "13 Jul 2026 10:50", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "JPMorgan resumes Denali Therapeutics stock coverage with Overweight rating", "summary": "JPMorgan has resumed coverage of Denali Therapeutics (NASDAQ:DNLI) with an Overweight rating and a $29 price target, citing its transition to a commercial biotech following the approval of Avlayah. The firm anticipates accelerated approval for DNL126 by late 2027 and highlights a", "url": "https://www.investing.com/news/analyst-ratings/jpmorgan-resumes-denali-therapeutics-stock-coverage-with-overweight-rating-93CH-4787580", "source_name": "Investing.com", "published_at": "2026-07-13T08:09:46", "published_display": "13 Jul 2026 08:09", "sentiment": "positive", "sentiment_pct": 81, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Denali Therapeutics (DNLI) Investor Day 2025 Summary", "summary": "Denali Therapeutics (DNLI) held its 2025 Investor Day, highlighting an expanded strategic focus beyond neurodegeneration to whole-body biotherapeutics using its Transferrin Receptor-enabled TransportVehicle (TV/Tivi) platform. The company aims for two near-term launches, tivideno", "url": "https://quartr.com/events/denali-therapeutics-inc-dnli-investor-day-2025_ojsNzDdr", "source_name": "Quartr", "published_at": "2026-07-10T17:09:55", "published_display": "10 Jul 2026 17:09", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "T. Rowe Price\u2019s 10% Stake and Avlayah Approval Could Be A Game Changer For Denali Therapeutics (DNLI)", "summary": "T. Rowe Price Investment Management has disclosed a 10.2% stake in Denali Therapeutics, shortly after the company secured FDA approval for its Hunter syndrome therapy, Avlayah, and sold a Rare Pediatric Disease Priority Review Voucher for $195 million. This institutional interest", "url": "https://www.sahmcapital.com/news/content/t-rowe-prices-10-stake-and-avlayah-approval-could-be-a-game-changer-for-denali-therapeutics-dnli-2026-07-09", "source_name": "Sahm", "published_at": "2026-07-10T15:09:55", "published_display": "10 Jul 2026 15:09", "sentiment": "positive", "sentiment_pct": 65, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Denali Therapeutics to Give Opening Plenary Address at Alzheimer\u2019s Association International Conference (AAIC) 2026 and Highlight Breakthroughs in Delivering Biologic Therapies Across Blood-Brain Barrier", "summary": "Denali Therapeutics will deliver the opening plenary address at the Alzheimer\u2019s Association International Conference (AAIC) 2026, with CEO Ryan Watts discussing advancements in treating neurodegenerative diseases, particularly Alzheimer's. The company will highlight its proprieta", "url": "https://www.manilatimes.net/2026/07/10/tmt-newswire/globenewswire/denali-therapeutics-to-give-opening-plenary-address-at-alzheimers-association-international-conference-aaic-2026-and-highlight-breakthroughs-in-delivering-biologic-therapies-across-blood-brain-barrier/2381996", "source_name": "The Manila Times", "published_at": "2026-07-10T02:40:30", "published_display": "10 Jul 2026 02:40", "sentiment": "positive", "sentiment_pct": 93, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Denali CEO to open AAIC 2026 with brain-delivery plan for Alzheimer\u2019s", "summary": "Denali Therapeutics (Nasdaq: DNLI) announced that co-founder and CEO Ryan Watts, Ph.D., will deliver the opening plenary address at the Alzheimer\u2019s Association International Conference (AAIC) 2026 in London. He will discuss advancements in neurodegeneration biology, biomarkers, a", "url": "https://www.stocktitan.net/news/DNLI/denali-therapeutics-to-give-opening-plenary-address-at-alzheimer-s-4ujviltygake.html", "source_name": "Stock Titan", "published_at": "2026-07-09T19:40:32", "published_display": "09 Jul 2026 19:40", "sentiment": "positive", "sentiment_pct": 76, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Denali Therapeutics stock hits 52-week high at $26.95", "summary": "Denali Therapeutics Inc. (DNLI) stock recently hit a 52-week high of $26.95, reflecting a 73.88% increase over the past year. The company's market cap is $4.24 billion, but InvestingPro suggests it might be overvalued. Recent positive news includes the sale of a Rare Pediatric Di", "url": "https://www.investing.com/news/company-news/denali-therapeutics-stock-hits-52week-high-at-2695-93CH-4784278", "source_name": "Investing.com", "published_at": "2026-07-09T14:40:32", "published_display": "09 Jul 2026 14:40", "sentiment": "positive", "sentiment_pct": 75, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Denali Therapeutics stock hits 52-week high at $26.95 By Investing.com", "summary": "Denali Therapeutics Inc. (DNLI) stock has reached a new 52-week high of $26.95, reflecting a 73.88% increase over the past year. The company's market cap is $4.24 billion, with InvestingPro suggesting potential overvaluation. Recent developments include selling a Rare Pediatric D", "url": "https://ca.investing.com/news/stock-market-news/denali-therapeutics-stock-hits-52week-high-at-2695-93CH-4727589", "source_name": "Investing.com Canada", "published_at": "2026-07-09T13:42:29", "published_display": "09 Jul 2026 13:42", "sentiment": "positive", "sentiment_pct": 94, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "DNLI Stock Surges 59.4% Year to Date: Is There More Room for Growth?", "summary": "Denali Therapeutics (DNLI) has seen its stock surge 59.4% year-to-date, driven by the FDA approval of Avlayah for Hunter syndrome and investor optimism. The approval establishes Denali as a commercial-stage company and validates its TransportVehicle platform, positioning it for l", "url": "https://www.tradingview.com/news/zacks:71454ca0c094b:0-dnli-stock-surges-59-4-year-to-date-is-there-more-room-for-growth/", "source_name": "TradingView", "published_at": "2026-07-08T17:41:29", "published_display": "08 Jul 2026 17:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "T. Rowe Price holds 10.2% of Denali Therapeutics (DNLI) in 13G/A", "summary": "T. Rowe Price Investment Management, Inc. has disclosed a 10.2% stake in Denali Therapeutics (DNLI) through a Schedule 13G/A filing. The filing indicates beneficial ownership of 16,178,963 shares, with T. Rowe Price holding sole voting power for 15,639,355 shares and sole disposi", "url": "https://www.stocktitan.net/sec-filings/DNLI/schedule-13g-a-denali-therapeutics-inc-amended-passive-investment-dis-df6d72096984.html", "source_name": "Stock Titan", "published_at": "2026-07-08T15:41:29", "published_display": "08 Jul 2026 15:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "DNLI - Denali Therapeutics Inc Volatility & Greeks", "summary": "This article provides a detailed financial overview of Denali Therapeutics Inc. (DNLI), including its latest stock performance, key financial ratios, volatility metrics, and insider/institutional ownership data. It covers various performance indicators like EPS, sales growth, and", "url": "https://finviz.com/stock?t=DNLI&p=m&ty=ocv&ov=chain_strike&s=40", "source_name": "Finviz", "published_at": "2026-07-06T18:13:45", "published_display": "06 Jul 2026 18:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Denali Therapeutics (DNLI) Looks Fully Valued Following Its 32% 30 Day Rally", "summary": "Denali Therapeutics (DNLI) has seen a significant rally, with a 30-day return of 32.33% and a one-year return of 75.83%. Despite trading at a discount to the average analyst price target, the company's Price-to-Book ratio of 4.4x (compared to the industry average of 2.8x) suggest", "url": "https://www.sahmcapital.com/news/content/denali-therapeutics-dnli-looks-fully-valued-following-its-32-30-day-rally-2026-07-05", "source_name": "Sahm", "published_at": "2026-07-06T01:13:46", "published_display": "06 Jul 2026 01:13", "sentiment": "negative", "sentiment_pct": 38, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "DNLI - Denali Therapeutics Inc Latest SEC Filings", "summary": "This page provides a detailed financial overview and snapshot of Denali Therapeutics Inc. (DNLI), including its latest stock performance, key financial metrics, insider and institutional ownership, and analyst recommendations. It also lists the company's SEC filings and provides ", "url": "https://finviz.com/stock?t=DNLI&p=w&r=y2&ty=lf&page=17", "source_name": "Finviz", "published_at": "2026-07-05T12:42:56", "published_display": "05 Jul 2026 12:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Denali Therapeutics stock stays focused on pipeline progress.", "summary": "Denali Therapeutics' stock performance is closely tied to the progress of its neuroscience and lysosomal disease pipeline, with investors monitoring development milestones. The company's focus on transport vehicle technology to cross the blood-brain barrier is central to its drug", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/denali-therapeutics-stock-stays-focused-on-pipeline-progress/69682194", "source_name": "Ad-hoc-news.de", "published_at": "2026-07-03T17:41:09", "published_display": "03 Jul 2026 17:41", "sentiment": "positive", "sentiment_pct": 65, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Amyotrophic Lateral Sclerosis Market Gains Momentum with Expanding Pipeline and Investment Potential by 2034 \u2013 DelveInsight | Helixmith, Sanofi, Denali Therapeutics, Transposon Therapeutics, GSK", "summary": "The Amyotrophic Lateral Sclerosis (ALS) market is projected to expand significantly by 2034, driven by an increasing disease prevalence, advancements in drug development, and growing regulatory support. The market experienced an estimated size of USD 850 million in the United Sta", "url": "https://www.barchart.com/story/news/3078022/amyotrophic-lateral-sclerosis-market-gains-momentum-with-expanding-pipeline-and-investment-potential-by-2034-delveinsight-helixmith-sanofi-denali-therapeutics-transposon-therapeutics-gsk", "source_name": "Barchart.com", "published_at": "2026-07-01T23:10:47", "published_display": "01 Jul 2026 23:10", "sentiment": "positive", "sentiment_pct": 71, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Denali Therapeutics Inc. \u2013 NASDAQ:DNLI", "summary": "This article focuses on the enterprise value to EBIT forward metric for Denali Therapeutics Inc. (NASDAQ: DNLI). It presents financial data related to this specific valuation ratio for the biotechnology company. The content appears to be a stub or a section from a financial data ", "url": "https://www.tradingview.com/symbols/NASDAQ-DNLI/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T23:11:29", "published_display": "27 Jun 2026 23:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Denali Therapeutics Inc. \u2013 NASDAQ:DNLI", "summary": "This article provides a financial statistic for Denali Therapeutics Inc. (NASDAQ: DNLI). Specifically, it presents the \"Price to sales forward\" metric for the company. The content appears to be a snapshot from a financial data platform, likely TradingView, showing overview inform", "url": "https://www.tradingview.com/symbols/NASDAQ-DNLI/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T08:10:48", "published_display": "27 Jun 2026 08:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Denali Therapeutics Inc Shs Unsponsored Brazilian Depositary Receipt Repr 0.2 Sh", "summary": "This page displays financial information for Denali Therapeutics Inc Shs Unsponsored Brazilian Depositary Receipt Repr 0.2 Sh (BMFBOVESPA:D2NL34), specifically its price-to-sales forward ratio. The content appears to be a financial data presentation page from TradingView, offerin", "url": "https://www.tradingview.com/symbols/BMFBOVESPA-D2NL34/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T01:40:02", "published_display": "27 Jun 2026 01:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Denali Therapeutics Inc. \u2013 NASDAQ:DNLI", "summary": "This page provides financial data, specifically the \"Price to earnings forward\" for Denali Therapeutics Inc. (NASDAQ: DNLI). It indicates that the company's stock is listed on the Nasdaq Stock Market and that the market was closed at the time of the data query, with no trades hav", "url": "https://www.tradingview.com/symbols/NASDAQ-DNLI/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T00:40:01", "published_display": "27 Jun 2026 00:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Denali Therapeutics Inc. Actuals & Estimates (DUS:4DN)", "summary": "This article provides an overview of Denali Therapeutics Inc. (DUS:4DN) financials, analyst estimates, and historical stock performance. It includes details on revenue, earnings per share, net income, key dates like the next earnings report on July 30, 2026, and a stock forecast ", "url": "https://www.tradingview.com/symbols/DUS-4DN/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T21:39:56", "published_display": "26 Jun 2026 21:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Denali Therapeutics Inc. \u2013 NASDAQ:DNLI", "summary": "This article provides the enterprise value to EBITDA forward for Denali Therapeutics Inc. (NASDAQ: DNLI). It appears to be a financial data snippet from TradingView, concentrating solely on this specific financial metric for the biotechnology company. The content confirms that no", "url": "https://www.tradingview.com/symbols/NASDAQ-DNLI/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T21:10:49", "published_display": "26 Jun 2026 21:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Denali Therapeutics Inc. Actuals & Estimates (NASDAQ:DNLI)", "summary": "This article provides an overview of Denali Therapeutics Inc. (NASDAQ: DNLI) stock, including current prices, historical performance, analyst forecasts, and financial data. It highlights the company's recent stock growth, market capitalization, and upcoming earnings report date, ", "url": "https://www.tradingview.com/symbols/NASDAQ-DNLI/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T20:40:02", "published_display": "26 Jun 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How Denali Therapeutics Inc. (DNLI) Affects Rotational Strategy Timing", "summary": "This article analyzes Denali Therapeutics Inc. (DNLI) using AI models to determine its impact on rotational strategy timing. It highlights strong sentiment across all horizons supporting an overweight bias and identifies no resistance levels above the current price, suggesting si", "url": "https://news.stocktradersdaily.com/news_release/150/How_Denali_Therapeutics_Inc._DNLI_Affects_Rotational_Strategy_Timing_062526083001_1782433801.html", "source_name": "Stock Traders Daily", "published_at": "2026-06-25T20:30:00", "published_display": "25 Jun 2026 20:30", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Denali Therapeutics options trading jumps to 2,291 contracts", "summary": "Denali Therapeutics Inc. saw a significant increase in options trading, with 2,291 contracts traded by Thursday afternoon. Call volume heavily outweighed put volume, and the July 17, 2026 $30 call option was particularly active. Coinciding with this, Denali Therapeutics shares ex", "url": "https://www.investing.com/news/stock-market-news/denali-therapeutics-options-trading-jumps-to-2291-contracts-93CH-4761252", "source_name": "Investing.com", "published_at": "2026-06-25T18:09:57", "published_display": "25 Jun 2026 18:09", "sentiment": "positive", "sentiment_pct": 61, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Denali to Sell Priority Review Voucher for $195M Cash Boost", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/denali-sell-priority-review-voucher-124000184.html", "source_name": "Zacks", "published_at": "2026-06-19T12:40:00+00:00", "published_display": "19 Jun 2026 12:40", "sentiment": "negative", "sentiment_pct": 42, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Denali Therapeutics to Sell its Rare Pediatric Disease Priority Review Voucher for $195 Million", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/denali-therapeutics-sell-rare-pediatric-122056186.html", "source_name": "MT Newswires", "published_at": "2026-06-18T12:20:56+00:00", "published_display": "18 Jun 2026 12:20", "sentiment": "negative", "sentiment_pct": 42, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Denali\u2019s rare disease voucher sale brings in $195 million", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxPb3BObzBPQzNOVUg3OU9xNGtkVG44Y0FyZUFVX0xHbmM3UXdzX3lHVHJ0bDNGdks1QVpmNDAtaGpJbk5mZDBLcVZUSk5rY2kxT0RHZ0NDRVlTTjBjOTVZSmNMZWNucEwwcTZiVW02d3VNaDV3REs5NFV2OUE2V0wzWkItRUJlaF91dmN1c2hKYk05VDJKaFhGNDZEVW5UQks4cXdwZEM4U25LQk0xV1NUVVFtVV81WFJMMlBZdkNPYw?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-18T07:00:00+00:00", "published_display": "18 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Denali Therapeutics (Nasdaq: DNLI) to sell pediatric priority review voucher for $195M", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxPNWY1aFJ1ZTkwR0dLQmtLRDItSmhtTHRqODVnNzlkbHZCeGNCQ3pjdGJqYnNmQmljbDk2aGRQVGI4UEc4Q21hMG5wS05SY0cxSDZIR3V6TGE4eXkwWldMUWVBX09zbWZESV9pa3RZSlNsdURPc25ENU5QTDVvdmZoWk1QdkRqSjk4eU1BalNIVWxpWDhfTzdwamNGa0Z4b2dDS0h5V3VEWjh2bzREMzdyNWZ3?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-18T07:00:00+00:00", "published_display": "18 Jun 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "UBS reiterates Denali Therapeutics stock rating citing Avlayah launch", "summary": "", "url": "https://news.google.com/rss/articles/CBMiyAFBVV95cUxOdzlmQTlNY2FCVzJLTW82RTl2cXRSc0F5cDB4NnB5YjNWRUV6a2ZHTURIRjR1S0FqQUNmLVRKeGxpeHJlekZmcVIyTlpmaFBhcHVDa0lzQ3dEdXNaYVVRVlBPb29haG9fdjI2b2N6ODlDanA5UDlNbFdhMTRjeW5hM0hPaXQyNUZicUVoWXJQTUxNS29rLXF5ZFQ1UkpqZnZFMlVaaWtSRWR5akIzSXJGdmdxOE9ScTJlLTZNbl9jTG41STRoVU1tVw?oc=5", "source_name": "Investing.com", "published_at": "2026-06-16T07:00:00+00:00", "published_display": "16 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What Makes Denali Therapeutics (DNLI) One of the Best AI Driven Biotech Names", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxPSWRBT3RMdVo2Tm1LYkVNRlRlTmhUclYwZkhfWlhncE1hdk9HdkY5ZFQyQ1lDU2J0YkZGYWVBQ2dvdGFEamQ3Nk90ajAwUmdMM1FybVdyNDJMbWhBVU91SWp2TlJrYXhLdm8yeVFCc25sRTJGV0hKU0FNYWFXRV90Nklka0NsMHNwR0dxdWt4d3Zic0xTOFBzamItWmVtQ3FGb0czOVNR?oc=5", "source_name": "Market source", "published_at": "2026-06-11T07:00:00+00:00", "published_display": "11 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Denali Therapeutics (DNLI) grants RSUs and stock options to director", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxNekNnanJHXzFXN3c0a0FEVHcwWG5CUTBaMGNDWUdhbDdOV0s0cW1NaVo5R0tQSlJfTkx5eGMwUDFlcENJcTJfWFBNaGNLN3J2d2FydzhtbW1yUHlIcjREQzgxenBGdVlTSDVqT2twTVgtRm5nYzhNR29xTDRyVmhJWnNYUTJjazRVR1V3ZUdlOWRyMEtndHVnQ21zNUhoblVFUE80anJzTFlHNFZEd3g1UzVSS0V2TW13?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-05T07:00:00+00:00", "published_display": "05 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Denali Therapeutics (DNLI) 2026 meeting backs board slate, auditor and executive pay", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxNazYzSTZIcmstZlpDTmJ5TVBGb09EcFowYnNvcWJwUE0zS3BHTGhXWUZUSUR5TlVBcWlMNnRuU2ZTZEE0SkMydXBDY05OWlo4TjZzZFVpcGRUellmQVZtdGx3aGNKX2x5dzRQbzJOSE9JOFkyTWktZHdCbVRUZUlFYUlxcE9HYXY5Y3dTYVVBT2lndzZwVDkyaGhEWWY2bjhURkRadF9tYVc1OWI1czRfS1FR?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-04T07:00:00+00:00", "published_display": "04 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Denali Therapeutics Inc. (DNLI): One of the Top Stock Picks of Jeff Bezos", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxNM2JzbzhYejFkcWFDYUhNNGZQX3BNcFJFUFVVQ0Y5T21iSDY4X3RLblROT0Z4QnpEZ2VDSHNQYnZ4RmwtRmdUSzIyV1RvbjNnWmVxeVg5UTN4dE9EaENRRGNXUTJzcFZDcmd2LXhwdFM4RUltNWNhSldRMDZ0bEpmcERtbHVxdGgwU0s4bGdNcVpQSjRlYWpMSVhHY2lVQQ?oc=5", "source_name": "Market source", "published_at": "2026-06-01T07:00:00+00:00", "published_display": "01 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Denali Stock Dips as Biogen-Partnered Parkinson's Disease Study Fails", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxPNzJEZFk3a2MxcHU0QjdKMEZpWDhmaXlMVUNGSnM1NERseVJ1YXlONlY4NzRoYmVQU3cyaXhsVFE0SEZYcTZkcHNvcjhxRFBZQW5TY0dKekI5ZmZQM3VNZUFxSlN4ZW9jSi1RaWtPdk9QVDY3RFRpdnRjWmhtdmdYV29GeTRRZFhSX28tNHczeGp5N2RxYmFCSHdMSGlxSFlTWDd2TnhB?oc=5", "source_name": "Market source", "published_at": "2026-05-22T07:00:00+00:00", "published_display": "22 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Denali\u2019s AVLAYAH Approval Shifts Focus To Valuation And Pipeline Potential", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-19T07:00:00+00:00", "published_display": "19 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Hedge Fund Wagers $36 Million on Biotech Denali After First FDA Approval", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwgFBVV95cUxOcGoyV29uOWdIZHVWZHFZYVYwUnlGcHNlNmNPNGsyUHlGN21qclN2RlBSMmNhUW1va3U3YjJ6N3k4UHFUQkQ1dUxNWHBCaGNOSEt5c0ozV1drcno5Y1BqOXFnVnd1Rl9QN0RKVUlKcFRrZWllQVJCVlhtTWM3MUcxWlRSaXhJNFFYRVBNanBSblZuNlFUdlJzQ3hhTXZ3US1OZVFad19PUnUxa0tlREtCZDB5aHN3QzhIQ2xQYWFjandSQQ?oc=5", "source_name": "The Motley Fool", "published_at": "2026-05-18T07:00:00+00:00", "published_display": "18 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FMR LLC increases visibility on Denali (DNLI): 6.67M shares disclosed", "summary": "", "url": "https://news.google.com/rss/articles/CBMiywFBVV95cUxNbkF0cFNZZmVjS1dNd0F2ZF90NTE1bUZsR3NvWlQwOUREOW52NkFoRXEwUjJVRjBTS0g4VkFheDNNZ1pxVm5pekJyclIyNHlxRTRFWVFFVWppSzNTTmEwcF9hNTB2Nm5MWGNoTFRjMG1aYXppNEVRc0ZlLTJ4Mi1nNWlJMkJEcE1Jcm1nUjNSbm1IRHloNjNTOWhSZWZJUW1QZmZRMG5LX2ZXQW5IMjZQbV9yLW13UGJibGwzVXNJa091MmdndTNwWjYxTQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Denali Therapeutics (DNLI) Is Down 8.2% After Takeda Exits DNL593 Collaboration And Returns Rights", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxPVy03b1FLTDBYZHRnQTVadzJ0ZlRPdjhFaTh2QXZDcUN4TkVDUVVKcXhBNWotMmRxaHJ5dWdkRDNpeWdLUHhNQWEySjUwNTJiaF9GMFA2YWNiX1VaRFZoYzBDTmJxbkluNktXTDg3aUo0YVd2OWI0eUhEbm1oOW1uUVg1dl8taERKTUpRaUg5eWFfR2FiRkhlSExPeWV6VndHR3R4Tw?oc=5", "source_name": "Market source", "published_at": "2026-05-04T07:00:00+00:00", "published_display": "04 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What Makes Denali Therapeutics (DNLI) One of the Best Biotech Stocks to Invest in", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxPZGU1Z0ZrTnFtWlBBZERaTUVTbXN0Wk02YzdScVc3U21VM2JSS25HcGItUllzbElxdWE4emo4MEd1aWZKSmpuVlBsSkZhMmVSY0xRSTdtdk1JZmhid2Y5SmZRRzNGeVdyNHBleV9IS0FWR1VJTXFhS21IMUF4U3ZhUERPNVJyMkRuLXZxQmFYRDFOelJtWTN1aHpESTY1ZFJ1dFlZczV3?oc=5", "source_name": "Market source", "published_at": "2026-04-29T07:00:00+00:00", "published_display": "29 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Denali Stock Falls as Partner Takeda Ends Collaboration Deal", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxQMTBvOVdzbWI3aG9iamN6RE9aUG1pdGxxZkk4TUZDaHg4aHJPLUpwWlRLOVNrblY3VGlIbnlFV2tYZEs3MVhrVm5Ka1h3ZFdQSGt4WjVrQndyUW1XQ3ZDaHFRZTluTmltNUJKdDh4UjNCWE1MajVkX1lLVi01Vk8wc2c5enVJZEVQbWc2YmJJcnFabTFOYzJVQk9hNWZQX2ZPVG1HTg?oc=5", "source_name": "Market source", "published_at": "2026-04-07T07:00:00+00:00", "published_display": "07 Apr 2026 07:00", "sentiment": "negative", "sentiment_pct": 22, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Takeda exits dementia drug pact, Denali targets trial data by 2026 end", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxNVURNZVUzSE85NGRuLXNPN3k4ejNfampqM0F1V01qWEh2RjBBM2RsdFZlckhkVnJWX3B2a2JYOERUQ0JqaVJ1UjdycVh3OHV4X3BGTXoxN2gyOVphNk5MUVZvVzJ0Y2FOSDNIVkhMVHFvUU5FaENxQ1Qxb2JzYjBKdHRrUEdtb28xX2tQdnVJNk9LakYteVY5SzNkVmNaVVhfcWlaamdJSElzdjQ0clMtNFdXSUxBR1NpRzR3VXhn?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-03T07:00:00+00:00", "published_display": "03 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is It Time To Revisit Denali Therapeutics (DNLI) After Recent Share Price Pullback", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-04-02T07:00:00+00:00", "published_display": "02 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Denali Wins FDA Nod for Hunter Syndrome Drug, Stock Up", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxQUGpMaFlnTzA2eUliR3A1RkJwWDFOMlF6b1RQZzVYbmZkYWdfWURGanQ1SDM0Vk96bUtwTnp4d2ZNNHp6UXNaN0E5enNOREw4LWxNWG9JWjNUWFJwZmlSLXVQLVY4Nmg1dE8xTy04YnhyQjQwRWdUVVFIR0F6Q0RPX2JMbUpld0wtc2kxLU5VSzB6VmhKSUNzVDJ2SQ?oc=5", "source_name": "Market source", "published_at": "2026-03-26T07:00:00+00:00", "published_display": "26 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Goldman Sachs raises Denali Therapeutics stock price target on FDA approval", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0AFBVV95cUxPU0hZYmtHbzZQclRJWDhzV1hfaVMtRGhoaDVxc0JNWVRkM2pXYjJPaTJKWHlqV3ZJTTl4UTdFV1hpYWZOalhMOXhXNjUyZ3R1LXFPRFhXNXhCZ1ZIbExCeDhqSmUxX3pNUk01eERaQi16d0xHWFphX2lGRl9XNGhVQ2lWaV9LLW96Q3RxVGE2dl9kT3A1OTRxdzZWVnZhaEYxNHlSMmlhMUZvQ2FXT1YwbXVxd0pGaDZ6M3JfSUVldWlJcnI3ZE1HV3VXLVl1WmVQ?oc=5", "source_name": "Investing.com", "published_at": "2026-03-25T07:00:00+00:00", "published_display": "25 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Early FDA wins: Corcept\u2019s Lifyorli, Denali\u2019s Avlayah", "summary": "", "url": "https://news.google.com/rss/articles/CBMikwFBVV95cUxQUzRWTzBFbklkUmVGcWl6OFMtdm5lN0FCcWlQWTA3S28yMHVfb1JRbXpSN1BMZjNVUWFIMEEtalRYMFBQbDk1SjNmVVFwMjJlQ0QwRm15UUNQRzRndHpOWXFxRUVuLXlTdWFPclpxdkI1VmdPd0lrWDZOMVhENlViYXhTVXNwWDlaWk15WnVSajF5SkU?oc=5", "source_name": "BioWorld News", "published_at": "2026-03-25T07:00:00+00:00", "published_display": "25 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Denali Gains 11.8% in a Month: Buy, Sell or Hold the Stock?", "summary": "", "url": "https://news.google.com/rss/articles/CBMieEFVX3lxTFBGUFhxSHNJUk9mWEc2SkxZamlPUjRGQy1KZGhlc1pFS3hLUDRfWTMwcXpDbzJYRHRjbzA4U0ZLdlE3T2FOWmdGdFFIck9TbnZQb2Rxb2F0NGtzQjdaUlNGNUNWRndrZzkxNVhlOHFFMkVCUjN3ZFlpUQ?oc=5", "source_name": "Market source", "published_at": "2026-03-11T07:00:00+00:00", "published_display": "11 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Denali Therapeutics Inc (DNLI) Stock Price Today & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiV0FVX3lxTE1qbklvMzFzWU9UR0MydVVSSDNvd0RMdFhtZi1GOUJiS0JneXpFUEg1NkljdWE1bXBTVG1vRHlubzl3V1pxN3UtV3ZuQ2VfRE83WUx2dDhaYw?oc=5", "source_name": "Gotrade", "published_at": "2026-01-25T15:56:45+00:00", "published_display": "25 Jan 2026 15:56", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Have Denali Therapeutics Insiders Been Selling Stock?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-01-11T08:00:00+00:00", "published_display": "11 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Denali Therapeutics (DNLI) the Most Promising Mid-Cap Healthcare Stock Under $50?", "summary": "", "url": "https://news.google.com/rss/articles/CBMijgFBVV95cUxNSWdDZVVSaGNvSWRRUWZ5UWhUWFl2c2w3TXJqQmtOcjlxTU1ZY0t2aHozdnJGMUxCNDRuMDFpMHZiRGUzSzhIWWp6SnRwSE5kX3QzVGV0UmlHZmZweVZXWnRKM1owODZlUlA4VjY5SVVsNnVmanIza0thODd4MTRzTHgzbng4b2FTYkMtTTZ3?oc=5", "source_name": "Market source", "published_at": "2025-12-22T08:00:00+00:00", "published_display": "22 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 100, "total_relevant": 59, "sentiment_summary": {"positive": 18, "negative": 6, "neutral": 35, "score": 57, "total": 59, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 79, "events": [{"event": "general", "label": "Market update", "weight": 17.05, "count": 31}, {"event": "earnings", "label": "Earnings", "weight": 5.5, "count": 12}, {"event": "analyst", "label": "Analyst action", "weight": 4.4, "count": 8}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 2.2, "count": 4}, {"event": "deals", "label": "Deals and strategy", "weight": 1.65, "count": 3}, {"event": "liquidity", "label": "Balance sheet", "weight": 0.9, "count": 1}], "positive_events": 18, "negative_events": 6}, "market_context": {"has_market_context": true, "latest_close": 25.68, "latest_week": "2026-07-10", "one_week_move": -0.6, "four_week_move": 18.6, "twelve_week_move": 24.8, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": 1.182908, "market_dynamics_buy_signal": false, "relative_strength": 21.385449, "fair_value_gap": 29.9, "fair_value_label": "Materially above fair value", "fair_value_tone": "negative", "expectation_direction": "undecided", "expectation_probability": 50.3329, "reaction_label": "Price digesting", "reaction_tone": "neutral", "market_sentence": "-0.6% over one week, +18.6% over four weeks, trend active, and materially above fair value."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 56, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 14}, {"label": "TradingView", "count": 9}, {"label": "Stock Titan", "count": 8}, {"label": "Investing.com", "count": 5}, {"label": "simplywall.st", "count": 5}, {"label": "Moomoo", "count": 2}, {"label": "Sahm", "count": 2}, {"label": "Finviz", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 51}, {"label": "Industry context", "count": 8}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 31}, {"label": "Earnings", "count": 12}, {"label": "Analyst action", "count": 8}, {"label": "Regulatory and legal", "count": 4}, {"label": "Deals and strategy", "count": 3}, {"label": "Balance sheet", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "57/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "79/100 classification confidence."}, {"label": "Company focus", "value": "51", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "1", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "-0.6% over one week, +18.6% over four weeks, trend active, and materially above fair value."}, {"label": "Latest direct headline", "value": "Positive", "tone": "positive", "text": "Denali Therapeutics Price Target Announced at $29.00/Share by JP Morgan"}], "updated_at": "2026-07-16T00:37:37.154706+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}